skip to content

Roche receives FDA De Novo authorization for cobas® pro i 601 platform with Ionify® Gabapentin assay, advancing automated mass spectrometry for routine clinical laboratories

InvestorsInvestor updates
view all, Investor updates

stay updated

get the latest news and updates to your inbox.